Loading...

Navigating the new landscape of second‐line treatment in advanced hepatocellular carcinoma

Sorafenib and lenvatinib are approved for first‐line treatment of patients with advanced hepatocellular carcinoma (HCC), and the efficacy of atezolizumab plus bevacizumab has been demonstrated versus sorafenib. Over time, first‐line treatment frequently fails, and regorafenib, cabozantinib, ramuciru...

Full description

Saved in:
Bibliographic Details
Published in:Liver Int
Main Authors: Rimassa, Lorenza, Wörns, Marcus‐Alexander
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2020
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7496898/
https://ncbi.nlm.nih.gov/pubmed/32432830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.14533
Tags: Add Tag
No Tags, Be the first to tag this record!